Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

D9302

Sigma-Aldrich

Diacerein

≥95% (HPLC)

Synonym(s):

1,8-Diacetoxy-3-carboxyanthraquinone

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C19H12O8
CAS Number:
13739-02-1
Molecular Weight:
368.29
EC Number:
237-310-2
MDL number:
MFCD00468030
UNSPSC Code:
41116107
PubChem Substance ID:
24894281
NACRES:
NA.25

Quality Level

200

Assay

≥95% (HPLC)

form

powder

SMILES string

CC(=O)Oc1cccc2C(=O)c3cc(cc(OC(C)=O)c3C(=O)c12)C(O)=O

InChI

1S/C19H12O8/c1-8(20)26-13-5-3-4-11-15(13)18(23)16-12(17(11)22)6-10(19(24)25)7-14(16)27-9(2)21/h3-7H,1-2H3,(H,24,25)

InChI key

TYNLGDBUJLVSMA-UHFFFAOYSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

Biochem/physiol Actions

Diacerin is an inhibitor of Interleukin-1B (IL-1B) production.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H315,H319,H335

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
SLCH5485
SLBW4566
SLBW4568
SLBT8119
SLBP2999V

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ren-Yeong Huang et al.
Medical hypotheses, 79(2), 165-167 (2012-05-16)
Periodontal diseases are chronic inflammatory diseases characterized by the destruction of the tooth-supporting structures. They are the most prevalent form of bone pathology in humans and act as a modifying factor of the systemic health of patients. Accumulating evidence has
Kuljinder Singh et al.
International journal of rheumatic diseases, 15(1), 69-77 (2012-02-14)
To evaluate clinical effectiveness of diacerein as an adjuvant to diclofenac sodium in treatment of Indian patients with symptomatic osteoarthritis (OA) knee. This is a prospective, double-blind, placebo-controlled and intention-to-treat study. An initial washout period of 1 week, was followed
N de Isla et al.
Bio-medical materials and engineering, 20(3), 227-233 (2010-10-12)
The FoxO family of Forkhead transcription factors functions at the interface of tumor suppression, energy metabolism and organismal longevity. FoxO factors are key downstream targets of insulin, growth factor, nutrient and oxidative stress stimuli that coordinate a wide-range of cellular
Ballari Brahmachari et al.
Clinical rheumatology, 28(10), 1193-1198 (2009-07-15)
The objective of this study was to evaluate the efficacy and safety of diacerein in early, symptomatic knee osteoarthritis in Indian population. Sixty-four patients of knee osteoarthritis fulfilling American College of Rheumatology Criteria were randomized to receive either diacerein or
Amit Kumar Aggarwal et al.
Drug development and industrial pharmacy, 37(10), 1181-1191 (2011-04-01)
Diacerein (DCN) is a new anti-inflammatory analgesic and antipyretic drug developed specially for the treatment of osteoarthritis. DCN is a poorly water-soluble drug with relatively low bioavailability. Therefore, the purpose of this study was to enhance the solubility and dissolution
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service